Background: Vatarakta vis-à-vis gout is a common condition in both primary care and specialist practice. Gout is a systemic disease characterized by manifestations of chronic under lying hyperuricemia, resulting in the deposition of monosodium urate crystals in various tissues. Gout is the most common of the crystal induced arthritis due to disturbed uric acid metabolism and precipitation of urate crystals in extracellular space of joints, periarticular tissue, bones, and other organs.
INTRODUCTION
Joint diseases are becoming the main health problem in the present era as a result of changes in diet, lifestyle, and environmental factors. Vatarakta vis-à-vis gout is a common condition in both primary care and specialist practice. 1 Although not life-threatening, it has a signi ficant impact on quality of life (QOL). Vatarakta vis-à-vis gout is a very painful condition, and it curtails the output or day-to-day work of the patient. It is the commonest crystal induced arthropathy occurring in men over 40 years of age, presenting usually in the form of "podagra" (acute onset of pain, erythema, and swelling of the first metatarsophalangeal joint). 2 It has been called as "the disease of kings" due to its association with rich foods and alcohol consumption. 3, 4 Gout is a crystal-deposition disease that results from chronic elevation of uric acid levels above the saturation point for monosodium urate monohydrate (MSUM) crystal formation and it is associated with intense pain and enhanced vascular permeability evidenced by edema and erythema that may extend beyond the joint margin. 5, 6 The fundamental biochemical hallmark of gout is hyperuricemia and can result from increased production or decreased excretion of uric acid or from a combination of the two processes. Uric acid is the end product of metabolism of purines. Elaborate descriptions of Vatarakta (gout) in traditional Indian medicine show that it was one of the main articular diseases in the past. 7 there is a definite need to explore more efficacious and radical cure to this illness. Ayurveda in its herbarium has lots of ayurvedic formulations which can fill up this gap. Based on the textual and clinical experience, compound drugs Amrita Guggulu and Pinda Taila were selected as hypouricemic agent for the clinical trial in patients of gout (Vatarakta). This study was planned to find out the efficacy and safety of Amrita Guggulu and Pinda Taila in hyperuricemia in gout patients. After examining the pharmacological properties and pharmacological actions of constituents of selected Amrita Guggulu and Pinda Taila, it appeared that this combination might be effective in the management of gout (Vatarakta). Therefore, in order to develop evidence-based data on the efficacy and safety of Amrita Guggulu and Pinda Taila in the management of gout (Vatarakta) on scientific parameters, the present clinical trial was conducted.
OBJECTIVES
To study the therapeutic efficacy and safety of two classi cal Ayurvedic formulations, Amrita Guggulu and Pinda Taila, in the management of hyperuricemia in gout (Vatarakta) patients.
MATERIALS AND METHODS

Study Design
The 
Study Participants
A total of 100 confirmed cases of primary gouty arthritis fulfilling the diagnostic criteria as recommended by the American College of Rheumatology were selected for the present study from the outpatient department of the Central Ayurveda Research Institute for Respiratory Disorders, Patiala, and Regional Ayurveda Research Institute for Urinary Disorders, Jammu, India, irrespective of their sex, religion, and socioeconomic status. Patients were screened in accordance with the inclusion and exclusion criteria mentioned in the protocol and were recruited in the study after obtaining written informed consent.
Inclusion Criteria
Patients of either sex aged between 25 and 65 years who presented themselves with at least 6 out of 12 criteria of American College of Rheumatology (1977), i.e., more than one attack of acute arthritis, maximal inflammation developing within 1 day of onset, monoarthritis attack, redness over affected joint, unilateral attack on the first metatasophalangeal (big toe) joint, unilateral attack involving tarsal joint, first metatasophalangeal (big toe) joint painful and swollen, suspected tophi, hyperuricemia (≥7.0 mg/dL), asymmetrical swelling within joint (X-ray), subcortical cysts without erosions (X-ray), negative culture from join fluid during attack, and those were willing and able to participate in the study for 14 weeks.
Exclusion Criteria
Patients with history of any trauma/fractured joint/ surgical/diagnostic intervention with reference to the 
Outcome Measures
Primary outcome measure was reduction in serum uric acid level from baseline to the end of 84th day. The secondary outcome measures were improvement in QOL using SF-36 (Research and Development) Health Survey Questionnaire, Patient's Global Assessment Scale, and Physician's Global Assessment Scale. The pain was assessed on Visual Analog Scale (VAS) score and the safety of the trial drug was assessed by laboratory parameters (liver and kidney function test) and occurrence of any adverse drug reaction/adverse event.
Study Interventions
The patients were administered Amrita Guggulu (Yoga Ratnakara; Vatarakta chikitsa, chapter 26; Both these quality assured Ayurvedic formulations were procured from Good Manufacturing Practicecertified Ayurvedic Pharmaceutical industries. After the end of treatment period of 12 weeks, patients were also followed without medications till 14th week.
Study Procedure
On the enrolment day at baseline (visit 1), patient's demographic profile, medical history, family history particularly related to Vatarakta vis-à-vis gout, sharirik prakriti, and vital parameters were recorded. Subsequent visits were planned at an interval of 2 weeks [14th day (visit 2), 28th day (visit 3), 42nd day (visit 4), 56th day (visit 5), 70th day (visit 6), and 84th day (visit 7)]. Patients were assessed and given study medications at each subsequent visit till 84th day. There was also a follow-up without medication after 2 weeks of 84th day visit, i.e., on 98th day. At the study site, data of all the patients were recorded in predesigned Case Report Forms (CRFs) and were also entered in electronic formats (e-formats) designed in MS-Excel with many data validation checks to ensure correct data entry. The Xerox copies of the CRFs along with the e-CRFs of all enrolled patients were sent by all the participating centers to the Council's headquarters periodically for verification. Details of clinical assessment and study schedule are given in Flow Chart 1.
Statistical Analysis
Primary outcome and secondary outcome measures, i.e., serum uric acid level, QOL (SF-36 Health Survey score), pain assessment on VAS scale, were analyzed as mean change in the response from baseline to 84th day by using paired t-test. A p-value of <0.05 was considered significant. All statistical analysis was performed using Statistical Package for the Social Sciences version 15.0.
OBSERVATIONS AND RESULTS
Demographic Profile of the Patients
In the study, a total of 100 patients were enrolled, out of which 8 patients dropped out during the course of the study. Intention-to-treat analysis was done and the data of all those patients who have completed at least 14th day visit were imputed by last observation carried forward (LOCF) method. Hence, data of a total of 100 patients were used for statistical analysis. Flow Chart 2 shows the outflow of the patients in the study.
The demographic profile of 100 patients shows that the mean age of the patients was 47.55 years; 97% patients were married, 89% were literate, 92% were above poverty line, 33% were desk workers. Table 1 shows the detailed demographic profile of the patients.
Effect of Amrita Guggulu and Pinda Taila on Clinical Features of Gout
After 84 days of treatment with trial drugs Amrita Guggulu and Pinda Taila, improvement was observed in clinical features. The effect of trial medications Amrita Guggulu and Pinda Taila on the complaints faced by the patients suffering from gout (Vatarakta) is shown in Table 2 .
Flow Chart 1: Study schedule; LFT: Liver function test; RFT: Renal function test
Flow Chart 2:
Outflow of the patients in the study 
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Effect of the Trial Drugs on Outcome Measures
Effect of Amrita Guggulu and Pinda Taila on Serum Uric Acid, VAS Score, and QOL in Patients of Gout
It was observed that mean serum uric acid at the baseline was 7.76 mg/dL and reduced to 6.5 mg/dL after trial period of 84 days, which is statistically significant (p < 0.001). The pain was assessed on VAS (0-10 cm). The mean VAS score at the baseline was 5.3 cm and it was reduced to 1.5 cm at the end of treatment period, i.e., 84th day, which is statistically significant (p < 0.001). Amrita Guggulu and Pinda Taila have also been found effective in improving the QOL of the patients as assessed by SF-36 health survey questionnaire. A statistically significant improvement in all the eight domains of SF-36 health survey questionnaire, viz., physical functioning, role limitations due to physical health, limitations due to emotional problems, energy/fatigue, emotional wellbeing, social functioning, pain, and general health, was observed (p < 0.001) ( Table 3) .
Effect of Amrita Guggulu and Pinda Taila on Patient's Global Assessment Scale Score (5-point Likert Scale) in Patients of Gout
Significant improvement was observed on Patient's Global Assessment Scale score (5-point Likert scale) from the baseline to the end of treatment period, i.e., 84th day (Graph 1).
Effect of Amrita Guggulu and Pinda Taila on Physician's Global Assessment Scale Score (5-point Likert Scale) in Patients of Gout
Significant improvement was observed on Physician's Global Assessment Scale score (5-point Likert scale) from the baseline to the end of treatment period, i.e., 84th day (Graph 2).
Effect of the Treatment on Safety Parameters
The laboratory safety parameters, viz., blood urea, serum creati nine, SGOT, and SGPT, were assessed at baseline and at the end of treatment period (Graph 3). Though some changes were observed from the baseline to the end of the treatment, these were within the normal range. The details are given in Table 4 .
DISCUSSION
Vatarakta viz-a-viz Gout has been recognized as a very painful form of acute and recurrent arthritis since antiquity and clear-cut descriptions of several disorders with symptoms of pain, inflammation and burning sensation in the joint are given in all medical books. Gout is caused by deposition of monosodium urate monohydrate (MSUM) crystals in joints and tissues, when serum uric acid levels exceed 6.8 mg/dl. It causes acute mono-or polyarticular arthritis as well as chronic inflammation, which leads to joint destruction. The stereotypical features of gouty arthritis are that urate crystals are directly activated with all of the major synovial cell types and result in the infiltration of neutrophils in both the inflamed joint fluid and the synovial membrane 5, 12, 13 . Activated neutrophils release proteolytic enzymes, free oxygen radicals, arachidonic metabolites and cytokines, which in turn bring about inflammation and tissue damage in acute gout 12, 14, 15 . It has been known that MSUM can regulate the expression of pro-inflammatory cytokines and help to propagate a local or systemic inflammatory process. Cytokines, such as tumour necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), and interleukin-8 (IL-8), have been found in symptomatic joints of arthritic patients and have been implicated in acute gouty arthritic 11, 16 . The goals of gouty arthritis treatment are anti-inflammatory therapy to manage the significant pain, swelling, and disability associated with acute attacks 17, 18 . The trial drugs Amrita Guggulu and Pinda Taila have proved to be anti-gout, anti-inflammatory and anti-hyperuricemic, as these combinations have produced statistically significant (Twak Vaivarnya) , in the patients registered for the current trial along with reduction in marker of hyperuricemia i.e. serum uric acid. There was also decrease in the level of VAS score, patient's global assessment scale score and physician's global assessment scale score. There was no significant increase in liver function test (ALT & AST) and renal function test (blood urea and serum creatinine), indicating the safety profile of these drugs. There were no clinically significant adverse events, either reported or observed, during the entire study period. The components of the formulation Amrita Guggulu is having potent anti-inflammatory 19, 20 , analgesic, antipyretic 35 , antiarthritic activity 32 , anti-mutagenic/anti-carcinogenic 28 , hypolipidaemic and hypocholesterolemic activities 33, 34 hepatoprotective 21, 22 , radio protective 23, 24 , anti-atherosclerotic 25, 26 , antiviral 27 , antioxidant 29, 30 , and adaptogenic 31 properties, which are constitutive qualities for any drug to act against hyper-uricaemia induced inflammation. These activities might be mediated by inhibiting TNF-α, IL-1β, IL-8, and NF-κB p65 protein expression in synovial fluid and synovial tissue, and the suppression of NF-κB might be responsible for the decrease of the levels of IL-6, IL-8, and TNF-α in synovial tissue.
Ayurveda considers hyperuricemia under the spectrum of Vatarakta which is a disease caused by avarana of rakta on vata or viceversa. The management of Vatarakta is by removing the margavarana and clearing the raktadushti. Here the rakta dushti can be the causative factor for impairment in uric acid metabolism and its consequent deposition in the joints causing the symptoms of redness, joint pain, swelling etc. The components of Amrita Guggulu can be said to have uricosuric and anti inflammatory actions as is proven in this study as there was positive response in the outcome measures. Guggulu, a chief component of Amrita Guggulu has proven to have anti-inflammatory and anti oxidant properties. [36] [37] [38] Amrita Guggulu also has action on alleviating the symptoms caused by the hyper immune reaction triggered by uric acid deposition in joints. Guduchi is described as the best drug for the disease Vatarakta and it has actions on rasavaha srotas and raktavaha srotas and it improves circulation in the affected joints also. Pinda Taila is described in the context of Vatarakta as a potent pain reliever (vatarakta rujapaha). Abhyanga with Pinda Taila over the inflamed joints causes alterations in peripheral circulation and might augment the movement of accumulated inflammatory materials into the circulation and this correlates with koshta gati from sakha. Pinda Taila soothes rakta and vata simultaneously and reduces the inflammation and brings about changes in cardinal symptoms. The changes seen in this study after using this combination for a period of 84 days was statistically significant. The SF-36 health survey consists of eight scaled scores. The eight sections are: physical functioning, role limitations due to physical health, limitations due to emotional problems, energy / fatigue, emotional well being, social functioning, pain and general health. Lower the score, more the disability. The higher the score, lesser the disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. Increase in the score in physical functioning, role limitations due to physical health, limitations due to emotional problems, energy / fatigue, emotional well being, social functioning, pain and general health components of quality of life was observed after the completion of trial, which indicates improvement in the quality of life. Hence, it can be said that the simultaneous use of Amrita Guggulu internally and Pinda Taila externally has significant therapeutic efficacy while having the added advantage of being safe to use for a continued period of time.
CONCLUSION
Amrita Guggulu and Pinda Taila in the dosage of 1000 mg internally and 10 ml externally respectively, twice daily, produced significant response in relieving the symptoms of hyperuricemia and also in reducing the levels of serum uric acid. This combination can be said to have anti-inflammatory, anti-hyperuricemic and anti-oxidant activity. The combination of Amrita Guggulu and Pinda Taila has proven to be effective, safe and tolerable in patients with hyperuricemia in reducing the symptoms and improving the quality of life. 
